| Joseph P Dusseau, MD | |
|
3578 Fishinger Blvd, Hilliard, OH 43026-7503 | |
| (614) 457-4806 | |
| (614) 457-0269 |
| Full Name | Joseph P Dusseau |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 3578 Fishinger Blvd, Hilliard, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114980463 | NPI | - | NPPES |
| 2387984 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 35082369 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohiohealth Home Health | Worthington, OH | Home health agency |
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Dublin Methodist Hospital | Dublin, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Ohio Primary Care Physicians, Inc. | 2769383785 | 488 |
News Archive
First identified in 2012, the MERS-coronavirus is capable of causing severe and often fatal pneumonia. There are no effective treatments for MERS.
Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
A study led by researchers at The University of Texas Health Science Center at Houston (UTHealth) showed that a hands-free ultrasound device combined with a clot-busting drug was safe for ischemic stroke patients.
Cone-beam breast CT provides exceptional tissue contrast and can potentially reduce examination time with comparable radiation dose to conventional 2D mammography, according to a new study by a team of researchers from the University of Texas M. D. Anderson Cancer Center in Houston.
Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.
› Verified 6 days ago
| Entity Name | Central Ohio Primary Care Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194705194 PECOS PAC ID: 2769383785 Enrollment ID: O20040114000204 |
News Archive
First identified in 2012, the MERS-coronavirus is capable of causing severe and often fatal pneumonia. There are no effective treatments for MERS.
Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
A study led by researchers at The University of Texas Health Science Center at Houston (UTHealth) showed that a hands-free ultrasound device combined with a clot-busting drug was safe for ischemic stroke patients.
Cone-beam breast CT provides exceptional tissue contrast and can potentially reduce examination time with comparable radiation dose to conventional 2D mammography, according to a new study by a team of researchers from the University of Texas M. D. Anderson Cancer Center in Houston.
Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph P Dusseau, MD 3578 Fishinger Blvd, Hilliard, OH 43026-7503 Ph: (614) 457-4806 | Joseph P Dusseau, MD 3578 Fishinger Blvd, Hilliard, OH 43026-7503 Ph: (614) 457-4806 |
News Archive
First identified in 2012, the MERS-coronavirus is capable of causing severe and often fatal pneumonia. There are no effective treatments for MERS.
Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
A study led by researchers at The University of Texas Health Science Center at Houston (UTHealth) showed that a hands-free ultrasound device combined with a clot-busting drug was safe for ischemic stroke patients.
Cone-beam breast CT provides exceptional tissue contrast and can potentially reduce examination time with comparable radiation dose to conventional 2D mammography, according to a new study by a team of researchers from the University of Texas M. D. Anderson Cancer Center in Houston.
Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.
› Verified 6 days ago
Dr. Derek Edward Stone, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4343 All Seasons Dr, Ste 220, Hilliard, OH 43026 Phone: 614-544-1100 Fax: 614-544-1101 | |
Kelsey Sicker, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4343 All Seasons Dr Ste 220, Hilliard, OH 43026 Phone: 614-544-1100 | |
Marsha Jayne Turner, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4343 All Seasons Dr, Ste 220, Hilliard, OH 43026 Phone: 614-754-4110 Fax: 614-544-1101 | |
Daniel Fleshman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3617 Heritage Club Dr, Hilliard, OH 43026 Phone: 614-777-5530 | |
Angela J Bhojraj, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3823 Trueman Ct, Hilliard, OH 43026 Phone: 614-876-9558 Fax: 614-876-9570 | |
Robert Lp Knight, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3960 Brown Park Dr Ste A, Hilliard, OH 43026 Phone: 614-642-4012 Fax: 614-675-7181 |